Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 6,018 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction dated Friday, July 17th. The stock was sold at an average price of $52.64, for a total value of $316,787.52. Following the completion of the transaction, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at approximately $2,424,282.56. This trade represents a 11.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $43.80, for a total value of $263,588.40.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $53.76 on Wednesday. The stock’s 50-day moving average is $46.03 and its 200 day moving average is $37.96. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $55.79. The firm has a market cap of $3.27 billion, a price-to-earnings ratio of -32.19 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. On average, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ELVN has been the subject of several research analyst reports. JonesTrading lifted their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. The Goldman Sachs Group lifted their price target on shares of Enliven Therapeutics from $59.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. HC Wainwright increased their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Finally, Mizuho upped their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $70.50.

Institutional Trading of Enliven Therapeutics

Several hedge funds have recently bought and sold shares of the business. Tudor Investment Corp ET AL bought a new stake in Enliven Therapeutics during the 3rd quarter valued at $334,000. Candriam S.C.A. lifted its stake in shares of Enliven Therapeutics by 31.1% in the first quarter. Candriam S.C.A. now owns 594,079 shares of the company’s stock valued at $23,288,000 after buying an additional 141,060 shares in the last quarter. Rock Springs Capital Management LP grew its holdings in shares of Enliven Therapeutics by 3.5% during the first quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company’s stock valued at $32,399,000 after buying an additional 28,095 shares during the last quarter. First Light Asset Management LLC acquired a new position in shares of Enliven Therapeutics during the first quarter valued at about $7,913,000. Finally, Siren L.L.C. bought a new stake in shares of Enliven Therapeutics during the first quarter worth about $29,252,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.